INTRODUCTION 1
Amblyopia is a condition in which the best-corrected visual acuity (BCVA) is impaired in one eye or, 2 less frequently, both eyes, even though no ocular abnormalities are generally present. Amblyopia develops 3 when one or both eyes have abnormal visual input (either physical or physiological) during the sensitive 4 period in childhood (from birth to 6 years). 1, 2 Amblyopia is most commonly caused by strabismus in very 5 young children (<3 years of age, 82%) 3 and by refractive errors (anisometropia, isoametropia) in older 6 children. 4, 5 In the clinical setting, moderate amblyopia is defined as a logarithm of the minimum angle of 7 resolution (logMAR) BCVA of ≥0.30 (Snellen equivalent: ≤20/40) and/or an interocular BCVA difference 8 of 0.2 logMAR or more (in cases of unilateral amblyopia). The prevalence of amblyopia in the general 9 population varies from 1.3% to 3.6%, and it is one of the most common causes of monocular visual 10 impairment in adults. 4, 6, 7 Patients with monocular amblyopia have a significantly increased risk of visual 11 impairment if vision in their "good" eye is lost as a result of trauma or disease. 8, 9 12 Amblyopia can be treated in early life, 10-12 but visual gains diminish in school-aged children because 13 of a decline in visual system neuroplasticity and, possibly, treatment compliance. 1, [13] [14] [15] Amblyopia is very 14 difficult, if not impossible, to treat in adults. 16 
15
An improved understanding of the neuronal mechanisms underlying amblyopia and adult brain 16 neuroplasticity [17] [18] [19] has led to the development of visual rehabilitation methods that can be used after the 17 critical period. [20] [21] [22] [23] [24] Experimental models of amblyopia are based on the effects of monocular deprivation 18 on the structure and function of the visual cortex. 25, 26 Using an animal model, Espinosa and Stryker
26
Improvements in these values were observed after treatment in both study groups ( Figure 4C ). At 10 1 weeks, the control group had improved by 0.181 ± 0.027 (95% CI: 0.126 to 0.236) and the fluoxetine 2 group had improved by 0.148 ± 0.026 (95% CI: 0.095 to 0.201, both p < 0.001). At 22 weeks, the control 3 group had improved by 0.221 ± 0.036 (95% CI: 0.150 to 0.293) and the fluoxetine group had improved by 4 0.197 ± 0.033 (95% CI: 0.131 to 0.262, both p < 0.001). Figure 4D shows the distribution of patients with 5 normal (³ 0.7) and impaired (< 0.7) crowded near visual acuity. 6
The proportion of patients with an improvement in at least one of the visual function parameters was 7 60% in both treatment groups after 10 weeks of treatment. Three months after treatment completion (22 8 weeks), this proportion had increased to 70% in the fluoxetine group and 64% in the control group. 9
Moreover, 73% of the fluoxetine group subjects and 70% of the control group subjects showed a clinically 10 relevant improvement in at least one visual function parameter at some point during the study . 11 Improvements in visual function parameters are summarized in Table 3 . 12
Our clinical study protocol also included prespecified subgroup analyses, which assessed the effect of 13 the severity of amblyopia (moderate/severe), binocularity (suppression/normal fusion), sex (female/male), 14 compliance with software-based training (³85%/<85%), and age (<40/³40 years) on changes in visual 15 acuity (logMAR). The subgroup analysis data are summarized in Table 4 . Although the differences were 16 not statistically highly significant (p = 0.048), there were more responders with normal fusion in the 17 control group (6/11; 54.5%) than in the fluoxetine group (1/9; 11.1%), whereas there were more 18 responders with suppression in the fluoxetine group (7/11; 63.6%) than in the control group (3/7; 42.9%). 19 Finally, the visual acuity gains were associated with training compliance (p = 0.012) in both treatment 20 groups (Table 4) . 21
Safety 23
A total of 66 adverse events (AEs) were reported after initiating study treatments. Fifty-eight (87.9%) 24
AEs occurred during treatment and 8 AEs occurred (12.1%) after treatment. Only 16 AEs (24.2%) were 25 related or possibly related to the study treatment and all were reported during the treatment period. Eleven8 (25) of the treatment-related AEs were reported following the 10-week treatment period and no AEs led to 1 study withdrawal. One subject in the fluoxetine group exhibited transient mild diplopia that resolved 2 spontaneously. Other reported AEs were not related to visual function. One serious adverse event (benign 3 ovarian cyst of moderate severity) occurred during the study, but it was not related to study treatment. 4
Amblyopia is a complex brain disorder that can restrict everyday life because of the visual limitations 7 it imposes. Despite good screening programs and effective childhood treatments, amblyopia remains a 8 common cause of lifelong visual impairment independent of location or ethnic origin.
4, 7, 9, 41 The 9 combination of adequate refractive correction and occlusion therapy (patching of non-amblyopic eye) has 10 been the mainstay therapy for amblyopia of all etiologies. However, the benefits of various forms of 11 occlusion therapy are greatest when therapy is started at an early age (<8 years). Therefore, early 12 amblyopia detection and treatment is the most important factor for obtaining successful visual outcomes. 13
Physiologically, the brain has the greatest plasticity during the critical period in early postnatal life. 14 However, recent evidence strongly indicates that the primary sensory cortex may remain plastic into 15 adulthood. [17] [18] [19] [20] [21] [22] [23] [24] [27] [28] [29] [30] This finding suggests that there is a physiological basis for treating amblyopia in 16 adulthood, which provides an opportunity to potentially alleviate this world-wide public health problem. 17
The current study examined whether fluoxetine, an SSRI known to modulate adult rat visual cortex 18 plasticity 18 , can enhance the effects of patching/computer-based perceptual training combination therapy 19 in adults with amblyopia. The treatment response was good in both the fluoxetine and placebo study 20 groups, with an overall visual rehabilitation success rate of 52%. In addition, 17% of patients achieved 21 normal visual acuity in the amblyopic eye (Table 3) . Our results are in agreement with those of Li et al. 40 , 22 who found that 33% of adult amblyopic subjects had a substantial improvement in visual acuity following 23 video game-based perceptual training. In addition, our subjects had an average gain of approximately 2 24 lines of vision (0.2 logMAR), which was similar to improvements observed with other published training 25 protocols.
38, 39
The change in visual acuity after 10 weeks of study medication/perceptual training therapy was not 1 significantly different between subjects taking fluoxetine and subjects taking a matching placebo. It may 2 be that 20 mg of fluoxetine, the dose typically used to begin treatment of depression, was too small a dose 3 to modulate neuroplasticity. It may also be that the training paradigm (new spectacles, patching, and 4 computerized perceptual training) was so effective that the 20-mg dose of fluoxetine did not provide any 5 additional benefit. Larger fluoxetine doses (up to 80 mg/day) are often used in depressed patients when the 6 initial dose does not have the desired therapeutic effect. In addition, the 10-week treatment period may 7 have been too short to maximize fluoxetine benefits and it is possible that a difference between treatment 8 groups could have emerged after a longer treatment period. 9
Although there is evidence that some amblyopia treatments may be additive (optical correction in 10 combination with patching or atropine) 32 , some reports have documented that all amblyopia treatment 11 effects may not be additive. The effects of multiple amblyopia treatment paradigms were not synergistic in 12 rodent models of amblyopia. 42 Furthermore, environmental enrichment and fluoxetine treatment have been 13
shown to induce similar levels of amblyopia recovery in rodents. 28 Therefore, it is possible that perceptual 14 training alone (with refractive correction) promotes the maximum amount visual cortex plasticity and that 15 further treatments do not have additive benefits. The current study was not designed to determine this and 16 future studies should include a group of subjects only treated with fluoxetine (no perceptual training). 17
However, a rodent study found that fluoxetine alone had no effect on vision.
18 Furthermore, there are no 18 prior reports of visual benefits from fluoxetine monotherapy in amblyopic patients, even though millions 19 of patients, and presumably thousands of amblyopic patients, have used the medication over the past three 20 decades. In addition, a recent placebo-controlled, double-blinded, clinical study showed that 20 mg/day of 21 fluoxetine for 19 days did not significantly affect visual perceptual learning in humans. 43 These prior 22 studies support the theory that 20 mg/day of fluoxetine may not be a large enough dose to effectively 23 modulate visual cortex plasticity in adult humans. 24 Subjects in the current study received new spectacles with the proper refractive correction at baseline. 25
Initiating the use of appropriate prescription glasses can improve amblyopia in children 44 and adults 45 . 26
Therefore, the use of new corrective lenses may have added to the visual gains observed in the current 27 study. However, adults have lower plasticity than children so the effects of glasses may have been less 1 prominent in our adult population. Furthermore, test-retest variability should be taken into account; this 2 was low in the present study because visual acuity was measured under the same conditions and in the 3 same locations by the same observers. Moreover, regression to the mean must be taken into account; 4 because our study was placebo-controlled, the regression to the mean was reduced because both groups 5 most likely exhibited an equal tendency. 6
We found that training compliance was well correlated with improved visual acuity. Therefore, the 7 training software used in the current study could potentially be used in the clinical setting to personalize 8 training and remotely monitor patient compliance. This would allow clinicians to adjust follow-up 9 intervals based on treatment response rates. Understanding early treatment responses would also aid in 10 determining which patients are likely to benefit from treatment and would allow for adjustment or 11 discontinuation of treatment on the basis of individual responses. If no improvement is detected despite 12 good compliance, treatment may be discontinued and the diagnosis of amblyopia may need to be 13 reconsidered. Follow-up visit schedules can also be determined based on perceptual training performance. 14 Our study had several limitations. First, we did not have a true no-treatment control group. However, in 15 both the placebo and fluoxetine groups, perceptual training compliance was well correlated with the 16 magnitude of vision improvement. This finding strongly suggests that perceptual training resulted in 17 neuroplasticity and subsequent visual benefits. Future clinical trials should include several control groups 18 to examine the effects of individual interventions and their combined effects. Furthermore, the dose of 19 fluoxetine and duration of its use should be varied in these studies. Second, the response to treatment was 20 remarkably variable in both treatment groups. This may have resulted from the large amount of variation 21 in amblyopia severity and etiology in our study population. Twenty-two subjects (52.4%) had abnormal 22 binocularity at baseline, 10 of which had improvements in binocularity with study treatment. In addition, 23 only 2 subjects with severe amblyopia had low contrast sensitivity at baseline. Contrast sensitivity deficits 24 are sometimes found to correlate with the visual acuity in the amblyopic eye. [46] [47] [48] . Both subjects exhibited 25 remarkable improvements in visual test results. Our results are in agreement with those of Zhou et al., 49 26 who showed that perceptual learning can improve visual acuity and contrast sensitivity in adult amblyopia 27 patients. Nine of our subjects (21.4%) had improved crowded near visual acuity (Table 3) . Hussain et al. 50 1 found a significant association between reduction in crowding and visual acuity improvement in 2 amblyopic adults. However, we did not find a significant correlation between visual acuity improvement 3 and crowding, contrast sensitivity, or binocularity. It should be noted that the number of subjects in these 4 subgroups was relatively small and that larger subgroups may have revealed additional statistically 5 significant findings. 6
In conclusion, both fluoxetine and the software-based perceptual training were safe and well-tolerated, 7 with fluoxetine treatment not offering further benefits over perceptual training. The training software used 8 in the study simultaneously determined training compliance and improvements in visual function and 9
showed that good training compliance is essential for treatment benefit. Therefore, software-based 10 training, combined with eye patching, may improve visual function in adult patients with amblyopia. 11
Furthermore, the computer program used here has the potential to become a robust tool for the treatment 12 of amblyopia. 13
14

MATERIALS AND METHODS 15
All study conduct adhered to the tenets of the Declaration of Helsinki and followed Good Clinical 16
Practices. This study was reviewed and approved by the Regional Ethics Committee of Tampere The following assumptions were made to calculate sample size: comparison of two equally sized groups, 26 an intergroup difference (fluoxetine vs. placebo) in the change in logMAR visual acuity of at least 0.15, astandard deviation (SD) of 0.15, and a subject drop-out rate of 10%. Thirty-four subjects needed to be 1 randomized to power the study to 80%, assuming a two-sided type I error rate of 5%. 2 3
Study subjects 4
Four eye clinics in Finland and Estonia enrolled 42 subjects between June 2011 and April 2013. Study 5 inclusion and exclusion criteria are fully described in Table 1 . Briefly, adult patients with monocular 6 amblyopia with no other ocular or neurological abnormalities were considered for enrollment. Included 7 subjects were 19 to 57 years of age and had moderate (0.3−0.6 logMAR difference) to severe (>0.6 8 logMAR difference) amblyopia due to myopic or hyperopic anisometropia (≤4.25 D) or congenital 9 esotropia. The lower limit for anisometropia was not set in the study protocol. The investigators 10 considered the amblyopia to be of the anisometropic type if no strabismus had been diagnosed in 11 childhood and the refractive error was at least 1 D of anisometropia, determined as the spherical 12 equivalent, in childhood. Patients with other primary forms of strabismus, extrafoveal (eccentric) fixation, 13 or who used antidepressant drugs in the past 6 months were excluded. 14 15
Study examinations 16
Eligibility, demographic data, medical history, relevant medication, vital signs, physical examination, 17 blood and urine samples (including urine pregnancy test for fertile women), and amblyopia were assessed 18 at screening. Amblyopia was confirmed at screening and was defined as an interocular ETDRS best-19 corrected visual acuity difference of at least two lines and/or a logMAR visual acuity between 0.30 and 20
1.10 in the amblyopic eye and 0.10 or better in the dominant eye. Prior to randomization, patients received 21 new spectacles based on non-cycloplegic refraction to ensure best-corrected vision during the study. 22
A thorough ophthalmic examination was conducted at each of the seven scheduled visits (at 23 weeks -2 (screening), 0 (randomization), 2, 6, 10, 14 and 22; Figure 1 ) during the 26-week study period. 24
Vision tests included the assessment of binocularity, visual acuity, crowded near visual acuity, and 25 contrast sensitivity and were performed with the refractive error corrected. In addition, presbyopic 26 correction was used for crowded near visual acuity testing in presbyopic subjects.
Binocularity was examined using the Bagolini striated glass test 51 before monocular testing. Lens 1 striations were placed at 135° before the right eye and 45° before the left eye using lorgnette frames. This 2 testing setup allows each eye to receive the same fusible image with each fixation streak oriented 3 perpendicular to the striations and 90° away from the other eye. The test enables the evaluation of 4 simultaneously perceived images with a minimal dissociative effect and it was performed at near (33 cm) 5
and distance (4 m) under normal lighting conditions. Binocularity was categorized as suppression (1 light 6 and only 1 line were seen), normal fusion (binocular single vision, BSV; 2 lines were seen as X and 1 light 7 at the center), anomalous retinal correspondence (ARC; harmonious if 1 light and 2 lines were seen, but 8 one of the lines was broken due to foveal suppression, or inharmonious if 1 light and 2 lines were seen, 9 but the lines did not cross at the center where the light was located) or diplopia (2 lights and 2 lines were 10 seen). However, none of the subjects had diplopia in the current study. Crowded near visual acuity was assessed using a specific crowded Landolt C ring chart booklet at a 21 distance of 40 cm. 53 Crowded near visual acuity was defined by the smallest line in which the subject 22 correctly identified at least 8 of 12 letters (³66.7%). The right eye was tested first in all tests requiring 23 charts. The contralateral eye was occluded during testing and charts were switched between eyes. All eye 24 examination test charts and Bagolini striated glasses tests were standardized and validated for trial 25 endpoint measurement. All staff that evaluated vision were masked to subject group assignment.
Treatment safety was assessed using ophthalmoscopy, biomicroscopy, intraocular pressure (IOP) 1 measurement, laboratory safety tests [hematology (hemoglobin, hematocrit, erythrocyte count, leukocyte 2 count, platelet count), clinical chemistry (alanine aminotransferase, alkaline phosphatase, aspartate 3 aminotransferase, creatinine, gamma-glutamyl transferase, potassium, sodium, urea), and urine analysis 4 (blood, glucose, ketones, protein, pH)], vital signs, and physical examination performed at screening and 5 at each study visit. Adverse events and changes in concomitant medications were recorded at each study 6 visit. 7 8
Study medication 9
Fluoxetine capsules were manufactured by Orion Corporation (Espoo, Finland) and the matching placebo 10 capsules were manufactured by Corden Pharma GmbH (Plankstadt, Germany). Study subjects were 11 randomly assigned to receive either 20 mg fluoxetine each day (hard capsule) or a matching placebo. 12
Randomization was done in a 1:1 fashion in blocks of 4 and was stratified by site. Randomization was also 13 stratified by amblyopia severity, determined using interocular visual acuity difference (moderate: 0.3-0.6 14 logMAR difference, severe: >0.6 logMAR difference). The randomization structure was designed by a 15 biostatistician and the final randomization list was generated by an independent person who had no 16 contact with study subjects or study data. Medication was pre-packed and serially numbered so that 17 subjects were assigned to a study group by giving them the next available medication number in the 18 sequence. A drug accountability log was maintained by study-authorized personnel. The receipt, dispense 19 and return of study medication was recorded in this log. Patients were instructed to return dispensed 20 medication bottles at the next visit, even if the bottles were empty. The number of capsules dispensed and 21 returned was reconciled against the number of days between the visits and any discrepancies were 22 accounted for. After 10 weeks of receiving study medication, subjects were weaned off the daily 23 medication (1 capsule every other day for the next 2 weeks, Figure 1B) . 24
All subjects completed daily computerized training with eye patching during the 10-week period of 1 receiving study medication ( Figure 1A) . The principle underlying the perceptual training software 2 developed for this study is fully described in the Electronic Supplementary Materials and is illustrated in 3 Figure 2 and Supplementary video 1. All subjects received new spectacles before randomization and were 4 instructed to wear an eye patch over their dominant eye while performing daily computerized perceptual 5 training. The training software was used to track training compliance, which was calculated by dividing 6 the total accomplished training time with the total prescribed training time. Training compliance was 7 automatically reported to the study site prior to each scheduled visit. 8
All subjects were given an eye patch and were instructed to wear it over the non-amblyopic eye for 9 1 hour each day. Subjects were also instructed to complete approximately 30 minutes of the computer-10 based training each day while they were wearing the patch and their spectacles. 11
The training period was divided into ten 1-week segments and each subject played an identical 12 composition of games each week. The maximum total training time over the 10-week training period was 13 35 hours. The training program was made up of seven different games wherein the performance was 14 primarily determined by visual acuity and contrast sensitivity and secondarily by attention and mental 15 effort. Thus, the training was primarily focused on visual acuity and contrast sensitivity and was aimed at 16 their improvement. A schematic illustration of the training game task design and composition is shown in 17 
Study outcomes 24
The primary outcome of the study was an improvement in visual acuity in the amblyopic eye, as measured 25 by the ETDRS chart, from baseline (week 0, randomization) to the 10-week visit (end of treatment). 26
Secondary outcomes included the change from baseline in binocularity, contrast sensitivity and crowdednear visual acuity to week 10 week. The persistence of changes observed at 10 weeks was also evaluated 1 at the end of the follow-up period (week 22). Treatment safety was assessed using adverse event incidence 2 and ophthalmological examination findings throughout the study. Exploratory outcomes included changes 3 from baseline in training measures at each study visit. 4 5
Data analyses 6
The primary analysis population was the full analysis dataset (FAS), which included all randomized 7 patients who had received at least one dose of study medication (intention-to-treat principle). A last 8 observation carried forward (LOCF) imputation was applied up to week 10 for subjects who did not 9 complete the study and those who were non-compliant with the treatment. 10
Differences in visual acuity and crowded near visual acuity between the two treatment groups were 11 evaluated using the repeated measurements of analysis of covariance (RM ANCOVA) method with 12 baseline values as a covariate. The model included the study center, treatment and time point (visit) as 13 main effects, and treatment by time point (visit) as an interaction effect. With regard to the primary 14 endpoint, differences between the treatment groups with regards to change in the logMAR visual acuity at 15 10 weeks (and a 95% CI for the difference) were estimated using RM ANCOVA models with a contrast. 16
A secondary RM ANCOVA analysis was used to compare the least square means between the treatment 17 groups at the end of the follow-up (22 weeks) period to determine if treatment effects were maintained. 18
Contrast sensitivity was not analyzed with RM models because of low variability in the dataset. Pearson's 19 chi-square test was used to compare categorical variables. Some binocularity categories contained a low 20 number of subjects. Therefore, differences between treatment groups in binocularity were evaluated using 21
Fisher's exact test. 22
Ophthalmology. 110, 1632-7; discussion 1637 (2003). for each training day. The total training duration per week was ~3.5 h, excluding the time spent on game 10 parameter adaptation. In all tasks, the subject responded with a single keyboard-button press or withheld 11 the response. Games 1 and 2 were single-or multi-object visual tracking tasks where complex shaped 12 objects moved along curved paths on screen and the subjects' task was to respond whenever they observed 13 a feature-change in any of the objects. Different game segments exhibited different numbers of to-be 14 attended objects (attentional loads 1, 2, 3, and 4). Prior to each game, there was a calibration period with 15 one (Game 1) or two (Game 2) objects during which the magnitude of the feature change (C) was adjusted 16 to yield a detection rate (HR) of 64-73%. Games 3 and 4 were visual-tracking games like Games 1 and 2 17 and had an identical calibration procedure and object mobility, but involved only attentional loads of 1 and 18 2, and exhibited in two out of four conditions six feature-wise distinct distractor objects to impose visual 19 crowding. 
Eligibility criteria
Age 18-60 years, male or female Diagnosed with amblyopia due to myopic or hyperopic anisometropia, or, congenital esotropia Visual acuity in the amblyopic eye ≥0.30 and <1.10 logMAR Visual acuity in the dominant eye ≤0.10 logMAR Anisometropia ≤4.25 (spherical equivalent in diopters) Judged to be otherwise healthy by the Investigator, based on medical history, brief physical examination, eye examination and clinical laboratory assessments Females of childbearing potential were eligible for the study provided (i) they have a negative urine pregnancy test at the screening visit and (ii) they agreed to use adequate contraception (e.g. oral, depot or implanted hormonal contraception, intrauterine device, surgical sterilization or partner vasectomy) from the screening visit until at least 4 weeks after the last dose of study medication
Exclusion criteria
Diagnosed with other reasons of strabismus (than infantile esotropia) as the primary reason for amblyopia History of any amblyopia therapy in the 2 years before the screening visit Any eye surgery less than 6 months before the screening visit Observed off-fixation by ophthalmological examination (extra-foveal/eccentric fixation) Other ophthalmological pathologies that may affect the patient's rehabilitation Pregnant, planning to become pregnant during the study, or breast feeding History of depressive illness or treatment with antidepressant medication within 6 months before the screening visit Use of psychiatric medication within 6 months before the screening visit Receipt of an experimental treatment for any disease within 4 weeks before the screening visit History or presence of illicit drug use or alcohol abuse History or presence of any medical or psychiatric condition or disease, or laboratory abnormality that, in the opinion of the Investigator, may place the patient at unacceptable risk or that could prevent the patient from completing the study 4 
